Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

MLA

Nelson, David R., et al. “Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients with Chronic Hepatitis C Virus Genotype 2 or 3.” Gastroenterology, vol. 139, no. 4, Oct. 2010, pp. 1267–76. EBSCOhost, https://doi.org/10.1053/j.gastro.2010.06.062.

APA

Nelson, D. R., Benhamou, Y., Chuang, W.-L., Lawitz, E. J., Rodriguez-Torres, M., Flisiak, R., Rasenack, J. W. F., Kryczka, W., Lee, C.-M., Bain, V. G., Pianko, S., Patel, K., Cronin, P. W., Pulkstenis, E., Subramanian, G. M., & McHutchison, J. G. (2010). Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology, 139(4), 1267–1276. https://doi.org/10.1053/j.gastro.2010.06.062

Chicago

Nelson, David R, Yves Benhamou, Wan-Long Chuang, Eric J Lawitz, Maribel Rodriguez-Torres, Robert Flisiak, Jens W F Rasenack, et al. 2010. “Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients with Chronic Hepatitis C Virus Genotype 2 or 3.” Gastroenterology 139 (4): 1267–76. doi:10.1053/j.gastro.2010.06.062.